Key facts
- South Korea's biopharmaceutical exports reached a record $6.6 billion in the January-September period.
- This represents a 15.8% increase from the same period last year.
- Biopharmaceutical exports accounted for approximately 73% of the country's total pharmaceutical exports of $9 billion during the nine months.
- In the third quarter alone, biopharmaceutical exports climbed 15.6% on-year to $2.07 billion.
- The United States was the largest export destination, with shipments totaling $1.07 billion.
- Seven of South Korea's top 10 export destinations for biopharmaceuticals are in Europe.
South Korea's exports of biopharmaceutical products reached a record $6.6 billion in the first nine months of this year, driven by robust demand in Europe and the United States, according to data released by the Ministry of Food and Drug Safety.
Shipments of biopharmaceutical products rose 15.8 percent from a year earlier to an estimated $6.6 billion in the January-September period. These exports accounted for approximately 73 percent of the country's total pharmaceutical exports of $9 billion during the same period.
In the third quarter alone, biopharmaceutical exports climbed 15.6 percent on-year to $2.07 billion. The United States was the largest export destination during the nine months, with shipments totaling $1.07 billion, representing 16.3 percent of all shipments sent abroad. Switzerland followed with $1.01 billion, and Hungary was third with $920 million.
Exports to Europe showed particularly strong growth, with seven of South Korea's top 10 export destinations located in the region. This growth was partly supported by strong demand for contract development and manufacturing organization (CDMO) services and biosimilar products.
